X-Chem, AstraZeneca deal

AstraZeneca elected to extend a May 2012 research deal to five years from two years. X-Chem will conduct drug discovery on at least 10 therapeutic targets per year. Under the terms of the extended deal, X-Chem will receive undisclosed R&D funding for each project and is eligible to receive up to $26 million in preclinical, clinical and sales milestones for each project AstraZeneca elects to license. ...